XIFIN Blog Fda

Follow Us
lale.white's picture

Termination of the BlueCard Program Runs Afoul of State and Federal Regulations

Submitted by lale.white on Tue, 2012-06-19 11:10
Tue, 2012-06-19 11:08
Blue plans attempting to reconcile the non-standard claims filing rules imposed by BCBS associated with the termination of the BlueCard program are running afoul of state and federal regulations; from non-adherence to HIPAA electronic standards to ignoring state assignment laws.
lale.white's picture

Who if anyone benefits from the dismantling of the BlueCard® program?

Submitted by lale.white on Tue, 2012-06-12 10:20
Tue, 2012-06-12 10:18
The new system turns a straightforward process into an unnecessarily complicated and expensive one. Is the BCBS Association, forcing the Blues to enforce their exclusivity arrangements that disadvantage regional labs and prohibit them from competing in the market place?
lale.white's picture

FDA’s Draft Companion Diagnostics Guidance Document

Submitted by lale.white on Fri, 2011-07-29 11:22
Fri, 2011-07-29 11:21
In our Perfect Storm: Part II webinar Mya Thomae at Myraqa outlined the FDA’s draft Companion Diagnostics Guidance Document as well as the RUO/IUO Draft Guidance.
lale.white's picture

Result of CMS' 7/18 Meeting

Submitted by lale.white on Mon, 2011-07-25 11:25
Mon, 2011-07-25 11:24
Details for the “Laboratory Public Meeting on Payment for New Clinical Laboratory Tests for 2012” meeting on July 18th CMS on the new AMA CPT codes for genetic tests on the clinical laboratory fee schedule (CLFS) are posted here...

Interested In Learning More? Contact us to learn how XIFIN can help your business. Call us at (858) 436-2995 or click here to complete a brief information request form.